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ABSTRACT
The importance of canonical transforming growth factor b (TGF-b) and bone morphogenetic protein (BMP) signaling during cartilage
and joint development is well established, but the necessity for noncanonical (SMAD-independent) signaling during these processes is
largely unknown. TGF-b activated kinase 1 (TAK1) is a MAP3K activated by TGF-b, BMP, and other mitogen-activated protein kinase
(MAPK) signaling components. We set out to define the potential role for noncanonical, TAK1-mediated signaling in cartilage and joint
development via deletion of Tak1 in chondrocytes (Col2Cre;Tak1
f/f) and the developing limb mesenchyme (Prx1Cre;Tak1
f/f). Deletion of
Tak1 in chondrocytes resulted in novel embryonic developmental cartilage defects including decreased chondrocyte proliferation,
reduced proliferating chondrocyte survival, delayed onset of hypertrophy, reduced Mmp13 expression, and a failure to maintain
interzone cells of the elbow joint, which were not observed previously in another Col2Cre;Tak1
f/f model. Deletion of Tak1 in limb
mesenchyme resulted in widespread joint fusions likely owing to the differentiation of interzone cells to the chondrocyte lineage. The
Prx1Cre;Tak1
f/f model also allowed us to identify novel columnar chondrocyte organization and terminal maturation defects owing
to the interplay between chondrocytes and the surrounding mesenchyme. Furthermore, both our in vivo models and in vitro cell
culture studies demonstrate that loss of Tak1 results in impaired activation of the downstream MAPK target p38, as well as
diminished activation of the BMP/SMAD signaling pathway. Taken together, these data demonstrate that TAK1 is a critical regulator
of both MAPK and BMP signaling and is necessary for proper cartilage and joint development.  2010 American Society for Bone and
Mineral Research.
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Introduction
L
imb development is a complicated process culminating in
the formation of a highly functional limb skeleton composed
of cartilage, bone, connective tissues, and mobile joints. The
limb skeleton originally derives from mesenchymal cells of
the lateral-plate mesoderm that migrate, condense, proliferate,
differentiate, and undergo terminal maturation. As condensed
mesenchymal cells undergo the process of chondrogenesis,
several layers of cells at prospective joint regions adopt a
nonchondrogenic fate, forming the mesenchymal interzone.
Interzone cells ultimately give rise to the synovium, joint capsule,
and articular cartilage tissues of adult synovial joints.
(1) Genetic
studies have implicated several signaling factors in the proper
formation andmaintenance ofjoints,includingWnt9a,Wnt4, Erg,
Noggin, Gdf5, Bmpr1a, and Bmpr1b.
(1–8)
Mesenchymal cells outside interzone regions complete the
process of chondrogenesis primarily through the activities of Sox
family transcription factors—Sox9, Sox5,a n dSox6.
(9,10) After initial
formation of the individual cartilage rudiments, coupled processes
of chondrocyte proliferation and maturation are responsible for
longitudinal growth. Chondrocyte proliferation serves as the initial
driving force of longitudinal growth, but ultimately proliferating
cells near the center of cartilage elements withdraw from the cell
cycle and undergo chondrocyte maturation or hypertrophic
differentiation. Progression of chondrocyte maturation can be
followed via examination of key markers of maturation:
Prehypertrophic and early hypertrophic chondrocytes express
Indian hedgehog (Ihh)a n dRunx2, whereas hypertophic chondro-
cytes generating a mineralizing matrix are characterized by type X
collagen (Col10a1) expression, and finally, the most terminally
hypertrophic chondrocytes express matrix metalloproteinase 13
(Mmp13), an enzyme that controls degradation and removal of the
cartilage matrix.
(11) Completion of chondrocyte maturation is
necessary for proper vascular invasion, establishment of the
marrow cavity, and normal growth plate development.
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1784The transforming growth factor b (TGF-b) superfamily
represents a group of molecules critical for normal skeletal
growth and development. Recent mouse genetic studies have
provided important insights into the contributions of each of
thesemolecules to the processesofchondrogenesis, chondrocyte
maturation, and joint morphogenesis. Mouse models lacking the
TGF-b type II receptor in chondrocytes (Col2Cre;Tgfbr2
f/f) exhibit
defects in the postnatal regulation of chondrocyte maturation
primarily within the axial skeleton.
(12) Deletion of Tgfbr2 in early
limb mesenchyme (Prx1Cre;Tgfbr2
f/f) resulted in delayed cartilage
formation, reduced chondrocyte proliferation, and malformation
of joints within the digits.
(13) Bone morphogenetic protein (BMP)
signaling molecules are also known to be important regulators of
chondrogenesis, chondrocyte differentiation, joint formation,
proliferation, and apoptosis.
(4,14–20).M i c el a c k i n gB M Pr e c e p t o r s
1a and 1b within cartilage (Col2Cre;Bmpr1a
f/f, Bmpr1b
þ/ ,a n d
Col2Cre;Bmpr1a
f/f;Bmpr1b
 / ) or lacking canonical BMP targets
Smads 1 and 5 within cartilage (Col2Cre;Smad1
f/f;Smad5
f/f)h a v e
reduced chondrocyte proliferation, delayed onset of chondrocyte
maturation, reduced proliferating chondrocyte survival, and
delayed progression of terminal maturation.
(16,17) Conditional
deletion of the BMP ligands, BMP-2 and BMP-4, using the Prx1Cre
transgene (Prx1Cre;Bmp2
f/f;Bmp4
f/f) resulted in shorter and thinner
limbs, delayed differentiation and marrow cavity formation,
disorganized clearance of hypertrophic chondrocytes, joint fusion
of the stylopod and zeugopod elements with little effect on the
autopod, and incomplete bone formation.
(14) Conventional
deletion of another BMP family member, Gdf5, also demonstrated
effects on the limb skeleton, resulting in decreased limb length
and various joint fusions/abnormalities.
(4,8,15)
TGF-b superfamily signaling is initiated when ligand binds to
the type II serine/threonine kinase receptor, leading to activation
of the type I receptor and induction of downstream signaling
mechanisms.
(21) Canonical TGF-b and BMP signaling occurs
via activation of receptor Smads (R-Smads) 2/3 and 1/5/8,
respectively. While the TGF-b and BMP canonical pathways play
critical and differential roles during chondrogenesis and
chondrocyte maturation, in vitro studies have demonstrated
recently a role for noncanonical signaling via the activation of
MAPKs. Noncanonical signaling by the TGF-b and BMP pathways
is thought to activate MAPK signaling via induction of
transforming growth factor b activated kinase 1 (TAK1).
(21) On
activation, TAK1 directly phosphorylates MKK 3/6, leading to the
subsequent phosphorylation and activation of p38.
(22,23)
The importance of TAK1 activation by TGF-b and BMP in
cartilage remains unclear. In vitro data suggest that noncanonical
signaling via MAPKs can regulate chondrogenesis, hypertrophic
differentiation, and proliferation via TGF-b-, Gdf5-, and BMP-
mediated activation of p38.
(24–29) Recent studies aimed directly at
MAPK pathway components have suggested that both over-
expressionandinhibitionoftheMAPKfactorscangeneratesimilar
in vitro chondrocyte phenotypes, leading investigators to
question whether MAPK signaling supports a single event or if
it is the balance of its activity that is important.
(24,27) Use of these
various gain- and loss-of-function mouse models has similarly
demonstrated that activation or inhibition of the MAPK pathway
results in analogous cartilage and bone phenotypes that manifest
primarily during postnatal development. Loss-of-function mouse
models, dominant-negative (dn) P38 and Atf2- deficient mice,
have demonstrated that disruption of MAPK signaling results in
postnatal chondrodysplasia, decreased chondrocyte proliferation,
and decreased chondrocyte survival.
(30–32) Meanwhile, transgenic
mice overexpressing constitutively active MKK6 in chondrocytes
are dwarfed, have decreased chondrocyte proliferation, delayed
onset of hypertrophic differentiation during embryonic develop-
ment, and a shortened zone of hypertrophic chondrocytes.
(33)
Recently, Shim and colleagues
(34) showed the importance of
TAK1 in postnatal chondrocytes when they analyzed a group of
Col2Cre;Tak1
f/f mice. Their analyses indicated that loss of Tak1 in
chondrocytes resulted in postnatal skeletal defects, including
decreased chondrocyte proliferation, increased apoptosis, elbow
dislocations, and deficient BMP and MAPK signaling. Despite the
clearpostnatalskeletalphenotypespresentedbythedisruptionof
MAPK signaling components, including TAK1, the roles of these
pathways have not been thoroughly examined during embryonic
skeletaldevelopment.Therefore,wesetouttodeterminewhether
TAK1 represents an important upstream component of the MAPK
and TGF-b/BMP signaling pathways during embryonic cartilage
and joint development by deleting floxed Tak1 alleles in cartilage
using a different Col2Cre transgenic line and in early limb
mesenchyme using the Prx1Cre transgene.
Materials and Methods
Tak1
f/f mice were generated as described previously.
(35) Tak1
f/f
mice were crossed with Col2Cre transgenic mice
(36) to delete
Tak1 floxed alleles within the developing cartilage. The
Col2Cre;Tak1
f/f mice are referred to as Tak1
Col2 mutants. Tak1
deletion within the early limb mesenchyme was performed by
crossing Tak1
f/f mice with the Prx1Cre transgenic mouse.
(37)
Prx1Cre;Tak1
f/f mice are referred to as Tak1
Prx mutants.
Skeletal preparation, histology, in situ hybridization, and
immunohistochemistry
Whole embryos for alcian blue/alizarin red skeletal staining were
prepared as described previously.
(38) Embryos harvested for
histology were dissected in PBS, fixed in 10% neutral buffered
formalin (NBF), decalcified in 14% EDTA, processed in paraffin, and
embedded prior to sectioning at 6mm. Hematoxylin and eosin
(H&E), safranin O, and fast green or alcian blue, hematoxylin, and
orange G stains were performed on various sections to identify
tissue/cell morphology of the limbs. In situ hybridization was
performedonlongitudinalforelimbsectionsusing
35Sradiolabeled
probes as described previously.
(39) Many of our antisense probes
have been described previously.
(3,38–40) Riboprobes not previously
described were generated from the following cDNA clones: Wnt9a
(30435371, Open Biosystems, Huntsville, AL, USA), Erg (40131153,
Open Biosystems), Gdf5,
(15) and Agc1 (5345931, Open Biosystems).
Immunohistochemistry was performed for p-Smad 1/5/8 (1:100
dilution; Cell Signaling, Danvers, MA, USA) and type II collagen
(Thermo Scientific, Freemont, CA, USA) on paraffin sections using
standard protocols.
Chondrocyte proliferation and apoptosis
For cell proliferation assays, pregnant female mice were
administered BrdU via i.p. injection 2hours prior to killing.
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described earlier. BrdU immunohistochemistry was performed
on three limb sections for three separate embryos of each
genotype using the Invitrogen BrdU Kit (Invitrogen, Carlsbad, CA,
USA). Proliferation rate is reported as the percentage of BrdU-
positive nuclei in the proximal humerus relative to wild-type
littermates. Changes in chondrocyte apoptosis were determined
using the In Situ Cell Death Kit (Roche, Indianapolis, IN, USA)
according to manufacturer’s protocol and reported as absolute
number of terminal deoxynucleotidyl transferase–mediated
deoxyuridine triphosphate–biotin nick end labeling (TUNEL)
þ
apoptotic cells in the proximal humerus. Cells were counted and
averaged for three separate wild-type and mutant sections from
three independent litters.
Western blot analysis of limb cartilage
Dissected cartilage for Western blotting was lysed using RIPA
buffer (150mM NaCl, 1.0% Triton-X, 0.5% sodium deoxycholate,
0.1% SDS, 50mM Tris. pH 8.0) containing minicomplete protease
inhibitor (Roche) and PhosSTOP phosphatase inhibitor tablets
(Roche).Whole-celllysatewasquantified,normalized,andrunon
10% Bis-Tris gels (Invitrogen). Blots were incubated with primary
antibodies including total TAK1 (Cell Signaling) and b-actin
(Sigma). Blots then were washed in Tris-buffered saline with
Tween-20 (TBST), incubated in secondary antibody, and
visualized using chemiluminescence (Pierce, Rockford, IL, USA).
Cell culture and signaling
Primary sternal chondrocytes were isolated from 2- to 3-day-old
Tak1
f/f mice as described previously
(41–43) or from E14.5 cartilage
elements of the limb. All cells were seeded as follows: 1 10
6
cells per well in a six-well plate and maintained in DMEM
containing 10% FBS and 1% penicillin/streptomycin. In vitro
deletion was performed using Ad5-CMV-GFP (control) or Ad5-
CMV-Cre viruses (Baylor Vector Development, Houston, TX, USA).
Cellswereinfectedfor48hoursandallowedtorecoverovernight
before treatment. For alkaline phosphatase staining, cells were
fixed in 4% paraformaldehyde, washed, and stained using NTB/
BCIP (Thermo Scientific).
Rat chondrosarcoma (RCS) cells were cultured in DMEM
containing 10% FBS and 1% penicillin/streptomycin.
(44) For
Western blotting, cells were serum-starved overnight, pretreated
with the cis-enol resorcylic acid lactone–selective TAK1 inhibitor
(TI-2), LLZ1640-2 (Bioaustralis, Smithfield, NSW, Australia),
(45) the
inactive homologue (TI-4), LLZ1640-4, or DMSO (Sigma) and then
treated for 60minutes with 100ng/mLof BMP2(Peprotech, Rocky
Hill, NJ, USA). Cells were lysed using NP-40 lysis buffer (150mM
NaCl,1%NP-40,50mMTris-HCl,pH8.0)containingmini-complete
protease inhibitor (Roche), PhosSTOP phosphatase inhibitor
tablets (Roche), 1mM sodium orthovanadate, 10mM NaF,
and 0.5mM okadaic acid. Lysates were run on 10% Bis-Tris gels
(Invitrogen), and antibodies used included TAK1, pSmad 1/5/8,
pP38, tP38, atubulin (Cell Signaling), and total Smad 1/5/8 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Gene expression
studies used RNA extracted with Trizol reagent (Invitrogen)
according to manufacturer’s protocol. Real-time RT-PCR was
performed on a RotorGene RT Machine (Qiagen, Valencia, CA,
USA) using 1mL of cDNA and PerfeCTa SYBR Green reagent
(Quanta BioSciences, Gaithersburg, MD, USA). For reporter
assays,cellsweretransfectedwith12 -SBEluciferasereporter
(46)
using Fugene-HD (Roche) according to the manufacturer’s
protocol. Cells were serum-starved overnight and pretreated
with TAK1 inhibitor for 30minutes prior to treatment with
100ng/mL of BMP2. Luciferase activity was measured 24hours
laterusingtheDual-PromoterLuciferaseAssayKit(Promega)and
normalized to Renilla luciferase. Triplicates of each treatment
group wereanalyzed,andstatistical significancewasdetermined
by t test.
Results
Loss of Tak1 within cartilage results in neonatal lethality
Tak1 is expressed throughout the cartilage and surrounding
tissues during endochondral bone development and during in
vitro chondrocyte maturation (Supplemental Fig. 1A, B).
Interestingly, cartilage deletion of Tak1 floxed alleles using a
Col2Cre transgenic lineresultedinneonatallethality immediately
following birth. X-ray and micro–computed tomographic (mCT)
analyses of newborn pups on postnatal day 0 (P0) demonstrated
that Col2Cre;Tak1
f/f (Tak1
Col2) mutant mice exhibit decreased
skeletal growth and have a significantly smaller ribcage
compared with littermate controls (Supplemental Fig. 2A). Alcian
blue and alizarin red skeletal staining for cartilaginous
components of the airway revealed an undermineralized hyoid
and a fusion of the hyoid to the larynx in Tak1
Col2 mutant pups
(Supplemental Fig. 2B). These data and the visual observation of
pups at birth indicated that Tak1
Col2 mutants do not survive
owing to respiratory distress.
Tak1
Col2 mutants display defects in cartilage proliferation,
maturation, and apoptosis
Examination of limbs isolated from alcian blue– and alizarin red–
stained embryos at 14.5 days of gestation (E14.5) clearly
demonstrated a decrease in the size of both forelimb (Fig. 1A,
A1andA2)andhindlimb(Fig.1A,A3andA4)elementsofTak1
Col2
mutants compared with wild-type littermate controls. Western
blot analysis performed on protein extracted from E14.5 humeri
cartilages verified deletion of Tak1 in chondrocytes of the
developing skeleton, although low levels of TAK1 protein
remained detectable likely owing to contaminating perichon-
drium and surrounding soft tissues inadequately removed
during isolation procedures (Fig. 1B). H&E staining of humerus
sections at E14.5 revealed a shorter limb in Tak1
Col2 mutants and
a much smaller hypertrophic region (Fig. 1C, C1 and C2).
Molecular analyses of chondrocyte maturation via in situ
hybridization demonstrated a delay in the onset of hypertrophy,
as evidenced by the decreased domain of expression for the
prehypertrophicmarkerIhh(Fig.1C,C3andC4),thehypertrophic
markerCol10a1(Fig.1C,C5andC6),andthecompleteabsenceof
the terminal hypertrophic marker Mmp13 (Fig. 1C, C7 and C8).
H&E staining of E15.5 humerus sections demonstrated that the
primary center of ossification had begun to form in both wild-
type and Tak1
Col2 mutant limbs(Fig. 1C, C9 and C10), butuniform
development of the marrow cavity in the Tak1
Col2 mutant was
incomplete owing to a continuous delay in chondrocyte
1786 Journal of Bone and Mineral Research GUNNELL ET AL.maturation (Fig. 1C, C9 abd C10, red dashed contours). Molecular
analysis of the maturational markers Ihh, Col10a1, and Mmp13
demonstrated that the spatial expression domains of Ihh (Fig. 1C,
C11 and C12) and Col10a1 (Fig. 1C, C13 and C14) are less well
separatedinTak1
Col2mutantscomparedwithlittermatecontrols,
whereas Mmp13 expression (Fig. 1C, C15 and C16) is markedly
reduced in Tak1
Col2 mutant limbs at E15.5. To determine if the
delayed marrow development was due to impaired vasculariza-
tion, we performed in situ hybridization to assess angiopoietin 1
(Angpt1)expressionwithinthedevelopingmarrowcavityofwild-
type and Tak1
Col2 mutant limbs. However, the results were not
remarkable (data not shown), suggesting that vascularization of
the primary center of ossification occurred normally, and the
primary defect is in chondrocyte maturation. Interestingly,
analyses of E18.5 histologic sections and in situ hybridization for
the chondrocyte maturation markers demonstrated a relatively
normal appearance of Ihh and Col10a1 expression domains in
Tak1
Col2mutantsatE18.5(Fig.1C,C17throughC22)aswellasthe
distinct presence of Mmp13 expression at the chondroosseous
junction, although Mmp13 expression remained slightly reduced
(Fig. 1C, C23 amd C24), and the overall growth of the elements
still was delayed.
To further address cartilage growth discrepancies between
Tak1
Col2 mutants and littermate controls, we performed BrdU
and TUNEL labeling experiments on humeral sections of E14.5,
E15.5, and E18.5 embryos. A representative section of BrdU
immunohistochemistry (IHC) in the proliferative cells of the
proximal humerus demonstrated that loss of Tak1 leads to
decreased chondrocyte proliferation at E15.5 (Fig. 1D, D1
and D2). Quantification of BrdU incorporation at E14.5 and
E15.5 revealed that the loss of Tak1 results in a significant
decrease (40%) in chondrocyte proliferation, but by
E18.5, chondrocyte proliferation is restored to levels near that
of wild-type littermate controls (Fig. 1D, D3). TUNEL labeling
studies further demonstrated that Tak1
Col2 mutants exhibit
significant elevations in resting/proliferating zone chondrocyte
apoptosis of the developing humerus at E14.5 and E18.5
(Fig. 1E; and data not shown). Collectively, these data
demonstrate that loss of Tak1 in cartilage resulted in early
delays in chondrocyte maturation, reductions in chondrocyte
Fig. 1. TAK1 regulates chondrocyte proliferation, maturation, and immature chondrocyte survival. (A) Alcian blue skeletal staining of forelimbs (A1, A2) and
hindlimbs (A3, A4) from wild-type and Tak1
Col2 embryos at E14.5. (B) Lysates from cartilage of E14.5 humerus immunoblotted using anti-TAK1 antibody. (C)
H em a to xy l inan de o sinsta in in gofE 1 4 . 5( C1, C2), E15.5 (C9, C10), and E18.5 (C17, C18)humerus sections. (C9, C10) Red dashed lines indicate the chondroosseous
junction. In situ hybridization for Ihh,Col10a1,a n dMmp13 at E14.5 (C3–C8), E15.5 (C11–C16), and E18.5 (C19–C24). (D) Representative IHC for BrdU of E15.5 wild-
type (D1) and Tak1
Col2 (D2) embryos. (D3) Quantification of BrdU of cells in the proximal humerus of wild-type (blue)a n dTak1
Col2 (red) embryos at E14.5, E15.5,
and E18.5. (D2) Quantification of TUNEL
þ cells in the proximal humerus of wild-type and Tak1
Col2 embryos at E18.5 (
ap<.05 versus wild type).
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apoptosis.
Tak1
Prx mice exhibit delays in both the onset and
progression of chondrocyte maturation
Owing to the neonatal lethality and interesting cartilage
phenotypes of the Tak1
Col2 mice, we generated Prx1Cre;Tak1
f/f
mice (Tak1
Prx) to determine whether TAK1 controls endochon-
dral ossification in a broader context during both embryonic and
postnatal development. While the Prx1Cre transgene targets
boththecartilageandsurroundingtissuesderivedfromtheearly
limb mesenchyme,
(37) it remains restricted primarily to the
appendicular skeleton and thus would avoid any potential
respiratory complications responsible for the neonatal death of
Tak1
Col2 mice. Many of these animals survive to the weaning
stage (3 to 4 weeks), although additional skeletal anomalies
affect their long-term feeding and survival (Supplemental
Fig. 2C).
We first analyzed the limb skeleton phenotypes of Tak1
Prx
mutant mice at E14.5 and E18.5. Prx1Cre mediated deletion of
Tak1wasverifiedbyimmunoblottingfortotalTAK1proteinusing
lysates obtained from isolated limb cartilage elements of E14.5
embryos (Fig. 2A). H&E staining (Fig. 2B, B1 and B2), as well as in
situ hybridization, on humeral sections from E14.5 wild-type and
Tak1
Prx mutants supports a role for TAK1 in promoting the onset
of chondrocyte hypertrophy because the expression domains of
Ihh (Fig. 2B, B3 and B4), Col10a1 (Fig. 2B, B5 and B6), and Mmp13
Fig. 2. TAK1 indirectly regulates columnar chondrocyte organization and the progression of terminal maturation. (A) Immunoblot for TAK1 protein
isolated from humerus cartilage of E14.5 wild-type and Tak1
Prx embryos. (B) Histology and in situ hybridization of E14.5 wild-type and Tak1
Prx humerus
sections for H&E (B1, B2), Ihh (B3, B4), Col10a1 (B5, B6), and Mmp13 (B7, B8). (C1–C4) Double-sided arrows indicate hypertrophic region. H&E staining of
proximal humerus from wild-type (C1, C3) and Tak1
Prx (C2, C4) embryos at E18.5. Black boxes (C1, C2) indicate region of  20 magnification. (C3, C4)
Brackets denote height of columnar zone of chondrocytes. In situ hybridization of E18.5 wild-type and Tak1
Prx humerus sections for Ihh (C5, C6), Col10a1
(C7, C8), and Mmp13 (C9, C10). (D) BrdU incorporation of E14.5 and E18.5 wild-type (blue bars) and Tak1
Prx (red bars) embryos. (E) Quantitation of TUNEL
þ
cells in the proximal humerus at E18.5 (
ap<.05 versus wild type).
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and level of expression. Interestingly, histologic examination of
Tak1
Prx embryos at E18.5 indicated that in addition to the early
delays in the onset of chondrocyte hypertrophy observed at
E14.5 (Fig. 2B), loss of Tak1 in surrounding mesenchymal tissues
delayed the progression of chondrocyte maturation toward
the terminal hypertrophic state, which was not observed in the
Tak1
Col2 embryos at this stage. H&E staining clearly demon-
strated that E18.5 Tak1
Prx mutants have thinner cartilage
elements and surrounding perichondrium, a disorganized and
shortened columnar zone of chondrocytes (brackets), and an
increased size of the hypertrophic zone (double-headed arrows)
(Fig. 2C, C1 through C4). In situ hybridization for chondrocyte
maturation markers was performed on the E18.5 humeral
sections of Tak1
Prx and wild-type embryos. Tak1
Prx mutants
exhibited reduced Ihh expression (Fig. 2C, C5 and C6), expansion
of the Col10a1 expression domain (Fig. 2C, C7 and C8)
corresponding to the increased size of the hypertrophic region,
and an expanded domain of Mmp13 expression within the
terminally hypertrophic chondrocyes at the chondroosseus
junction (Fig. 2C, C9 and C10). Assessment of BrdU incorporation
at E14.5 and E18.5 in Tak1
Prx embryos reveals that in addition to
the decreased proliferation seen at E14.5 in Tak1
Col2 embryos,
loss of Tak1 in limb mesenchyme results in a decrease in
proliferation that persists at E18.5 (Fig. 2D). Similar to Tak1
Col2
mutants, Tak1
Prx mice exhibited increased apoptosis in pro-
liferating chondrocytes without any apparent change in
apoptosis at the ends of the growth plate (Fig. 2E). Taken
together, these data argue that TAK1 not only regulates
chondrocyte proliferation, immature chondrocyte survival, and
the onset of chondrocyte hypertrophy in cartilage but also
controls the organization of columnar chondrocytes and the
progression of chondrocyte terminal maturation via signaling
within adjacent mesenchymal derived tissues.
Loss or inhibition of TAK1 delays normal and BMP-
induced chondrocyte maturation
To further define the role of TAK1 in regulating chondrocyte
development, we performed in vitro chondrocyte maturation
experiments using Tak1
f/f sternal chondrocytes infected with Cre
and control Gfp adenoviruses (Ad5-CMV-Cre-GFP and Ad5-CMV-
GFP) or wild-type sternal chondrocytes treated with a pharma-
cologic TAK1 inhibitor or inactive homologue. The sternal
chondrocyte model is a well-developed in vitro model of
chondrocyte maturation
(41–43) that was well suited for our study
because cartilage in thesternum ofTak1
Col2mutantsdemonstrates
maturational defects similar to those noted in Tak1
Col2 developing
limbs (Supplemental Fig. 3B). Alkaline phosphatase staining
revealed a significant delay in chondrocyte maturation, as
evidenced by the decreased staining over an 8-day differentiation
period in Tak1-deleted cultures relative to Green Fluorescent
Protein(GFP) controls(Fig.3A).Inordertoverifythatthisdifference
in staining and maturation was not due to an absence of cells or a
Fig. 3. TAK1regulatesnormalandBMP-mediatedchondrocytematuration.(A)Alcianblueandalkalinephosphatase (AP)stainingofsternalchondrocytes
isolated from Tak1
f/f pups and infected with Ad5-CMV-GFP (control) or Ad5-CMV-Cre. (B) RT-PCR for exon 1 of the Tak1 gene on mRNA isolated from
primary sternal chondrocytes (B1). Immunoblot for total TAK1 in lysates isolated from primary sternal chondrocytes after infection (B2). (C) Wild-type
primary sternal chondrocytes treated daily with DMSO, 3mM TI-2 (LLZ1640-2), or 3mM TI-4 (LLZ1640-4) and stained for AP on indicated days. (D)A P
staining of wild-type primary sternal chondrocytes treated every other day with DMSO or TI-2 (3mM) and either no treatment, TGF-b (5ng/mL), or BMP-2
(100ng/mL). (E) AP staining of Ad-GFP- and Ad-Cre-infected primary sternal chondrocytes in untreated and BMP-2-treated (100ng/mL) culture.
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blue, demonstrating that Tak1-deleted cultures maintained cell
viability and the ability to produce matrix (Fig. 3A). The efficacy of
the Cre-mediated deletion was approximately 85%, as determined
by RT-PCR (Fig. 3B, B1) using primers designed to exon 1 of Tak1.
Additionally, immunoblots for total TAK1 on whole-cell lysates
following Cre infectiondemonstratedanear-completelossofTAK1
protein (Fig. 3B, B2). Similar chondrocyte maturation experiments
also were performed using daily treatments of the selective TAK1
inhibitorLLZ1640-2(TI-2),theinactivehomologueLLZ1640-4(TI-4),
or DMSO as an additional negative control. Treatment of sternal
chondrocyte cultures with the TI-2 inhibitor (3mM) displayed a
robust suppression in chondrocyte maturation compared with
either DMSO or TI-4 inactive homologue (3mM) treatments (Fig.
3C). Identical effects were observed using primary chondrocytes
isolated from E14.5 cartilage elements and treated with the TI-2
TAK1 inhibitor (Supplemental Fig. 4A). Treatment of sternal
chondrocyte cultures with 3mM TI-2 every other day (Fig. 3D)
or with daily TI-2 treatments at reduced concentrations (data not
shown) resulted in a less severe suppression of chondrocyte
maturation.
TodetermineifTAK1isrequiredforTGF-bsuperfamilysignaling
and the subsequent regulation of chondrocyte maturation, we
treated sternal chondrocyte cultures with either TI-2 or DMSO in
the presence or absence of TGF-b1 (5ng/mL) or BMP-2 (100ng/
mL)recombinantproteins.InordertovisualizetheBMPandTGF-b
effects on alkaline phosphatase (AP) staining, we treated cultures
with 3mM TI-2 every other day. AP staining demonstrated that
DMSO control cultures underwent normal chondrocyte matura-
tion during the 8-day differentiation period. Treatment with TGF-
b1significantlyimpairedAPstainingandchondrocytematuration,
whereas BMP-2 treatment enhanced or accelerated chondrocyte
maturation compared with the DMSO-treated control (Fig. 3D).
Treatment of these cultures with TI-2 resulted in decreased AP
staining in both the presence and absence of BMP-2 (Fig. 3D).
Interestingly, when the same TAK1 inhibitor treatments were
performedinthepresenceofTGF-b1,TI-2didnotaffecttheability
of TGF-b1 to suppress chondrocyte maturation (Fig. 3D). Similar
experiments also were performed using Tak1
f/f sternal chondro-
cytes infected with Cre and control Gfp adenoviruses. Cre-
mediated deletion of Tak1 resulted in impaired normal and BMP-
2-induced chondrocyte maturation, as measured by AP staining,
during a 5-day maturation period (Fig. 3E). All these data indicate
that loss of Tak1 or inhibition of TAK1 function disrupts BMP- but
not TGF-b-mediated effects on chondrocyte maturation.
Loss or inhibition of TAK1 impairs both MAPK and BMP
signaling pathways
To identify the potential molecular mechanisms underlying
the impaired BMP responsiveness and chondrocyte maturation
observed within TAK1-inhibited or -deficient cultures, we first
performed studies analyzing the activation of canonical and
noncanonical BMP signaling targets Smad 1/5/8 and p38,
respectively. Treatment of sternal chondrocytes with
TAK1 inhibitor TI-2 (LLZ1640-2, 3mM) resulted in decreased
Smad 1/5/8 and p38 phosphorylation (Fig. 4A, A1), as well as
decreased luciferase activity from the BMP-responsive reporter
12 -SBE (Fig. 4A, A2). To further support our findings, we
verified that loss of Tak1 via Cre-mediated deletion decreased
BMP-2-induced phosphorylation of Smads 1/5/8 (Fig. 4B).
Additionally, treatment of RCS cells with varying concentrations
of TI-2 demonstrated a dose-response for TAK1 regulation of
Smad 1/5/8 phosphorylation, noggin expression, and the
induction of the 12 -SBE luciferase reporter (Supplemental
Fig. 4C). Collectively, these data suggest that TAK1 affects both
canonical and noncanonical BMP signaling in vitro.
Fig. 4. TAK1 regulates both MAPK and BMP signaling. (A1) Immunoblot of whole-cell lysates isolated from control and TI-2 (LLZ1640-2)–pretreated,
serum-starvedwild-typeprimarychondrocytes stimulatedwithBMP-2(100ng/mL)for1 hour. (A2) 12 -SBEluciferase assay performedon serum-starved
wild-type primary sternal chondrocytes pretreated with DMSO or TI-2 and stimulated BMP-2 for 24hours. (B) Immunoblot from primary sternal
chondrocyte whole-celllysates afterAd-Cre-mediated deletionof TAK1.(C) Quantification of pSmad1/5/8 IHC on humerusof E14.5 wild-type and Tak1
Col2
embryos (
ap<.05 versus DMSOþBMP-2 control).
1790 Journal of Bone and Mineral Research GUNNELL ET AL.To directly assess the effect of Tak1 deletion on canonical BMP
signaling in vivo, we performed IHC for p-Smad 1/5/8 on
histologicsectionsofthehumerusfromE14.5wild-typeandTak1
mutants. Analyses identified a significant decrease ( 32%) in the
number of p-Smad 1/5/8 staining nuclei in the proliferating and
prehypertrophic chondrocyte regions of Tak1 mutants (Fig. 4C).
Furthermore, in situ hybridization of Tak1 mutant growth plates
exhibit reduced levels of the BMP target gene Id1 (data not
shown). These data strongly suggest that TAK1 plays an
important role in regulating the BMP signaling pathway during
chondrocyte maturation in vivo.
Tak1
Col2 and Tak1
Prx mutants exhibit additional defects in
joint and skeletal development
Whole-mount alcian blue and alizarin red staining of E18.5
Tak1
Col2 and Tak1
Prx embryos revealed additional abnormalities
during skeletal development caused by the tissue-specific
deletions of Tak1. Targeted deletion of Tak1 in type II
collagen–expressing cells resulted in a shorter axial skeleton, a
domed-shape skull, a smaller ribcage with delayed chondrocyte
maturation, cervical vertebral fusions, and a single joint fusion of
the radius and humerus within the appendicular skeleton
(Fig. 5A, A1 through A8 and Supplemental Fig. 3A, B). Deletion of
Tak1 in the early limb mesenchyme did not alter the size of the
ribcage, although it did result in an incomplete fusion of the
sternumatmidline(SupplementalFig.3C).Theaxialskeletonwas
not significantly affected in these mutants (Fig. 5A, A9 and A10)
because most axial cartilages are not targeted by the Prx1Cre
transgene. Tak1
Prx embryos did, however, exhibit humeroradial
fusions in the forelimbs (Fig. 5A, A15 and A16) identical to those
observed in Tak1
Col2 embryos. Skeletal staining of Tak1
Prx
embryos also exhibited an absence of the deltoid tuberosity
(Fig. 5A, A11 and A12), patellar fusions of the knee (Fig. 5A, A13
and A14), and multiple other joint fusions in both the forelimbs
and hindlimbs (Fig. 5A, A11 through A16, C, C1 through C8, and
Fig. 5. TAK1 is required for normal skeletal development and joint morphogenesis. (A) Alcian blue and alizarin red staining of E18.5 wild-type, Tak1
Col2,
andTak1
Prxembryos.Blackarrow(A11,A12)indicatesdeltoidtuberosityandfusionofthepatella(A13,A14)andhumerus(H),radius(R),andulna(U)at the
elbow (A7, A8, A15, A16). Red arrows (A7, A8, A15, A16) indicate fusion of humerus and radius. (A15, A16) Yellow arrows indicate lateral fusion of the
humerus (H) and ulna (U). (B) H&E staining of E18.5 wild-type and Tak1
Prx embryos at the lateral humeroulnar joint (B1, B2), the femorpatellar joint (B3, B4),
and the lateral aspect of the knee joint (B5, B6). (B7–B10) Alcian blue, hematoxylin, and orange G staining of carpals (C5, C6) and tarsals (C7, C8) at E18.5 in
wild-type and Tak1
Prx embryos. (C) H&E staining of the humeroradial joint of wild-type (C1, C3, C5, C7), Tak1
Col2 (C2, C4), and Tak1
Prx (C6, C8) embryos at
E14.5 ( 20 magnification) and E18.5 ( 10 magnification).
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Prx limb sections
at E18.5 highlights additional fused-cartilage elements, including
frequent humeroulnar fusions (Fig. 5B, B1 and B2), patellar knee
fusions (Fig. 5B, B3 and B4), occasional lateral knee fusions
(Fig. 5B, B5 and B6), fusion of the carpals (Fig. 5B, B7 and B8), and
fusion of tarsal elements (Fig. 5B, B9 and B10). Of note, Tak1
Prx
mutant knees also lacked histologically defined synovial or
meniscaltissues atE18.5(Fig.5B,B3andB4,anddatanotshown).
Since the elbow joints for both Tak1
Col2 and Tak1
Prx embryos
displayed cartilaginous fusions, we compared histologic sections
from the mutant and wild-type joints at E14.5 and E18.5 to
determine the onset and extent of the defects (Fig. 5C, C1
through C8). At E14.5, mutant embryos showed the appearance
of loose mesenchymal cells surrounding the joint region, but in
place of a well-defined joint containing interzone cells, there
existed only disorganized round mesenchymal-like cells that
were morphologically distinct from the adjacent epiphyseal
chondrocytes. (Fig. 5C, C1, C2, C5, and C6). By E18.5, when the
joint is more mature, the Tak1
Col2 and Tak1
Prx mutants lacked
defined synovial tissues within and surrounding the fused elbow
joints, whereas intervening round mesenchymal-like cells
developed into regions of disorganized chondrocytes exhibiting
little histologic staining for proteoglycans (Fig. 5C, C3, C4, C7, and
C8, and data not shown).
To more specifically identify the cellular and molecular
changes associated with the joint defects observed in Tak1
Prx
and Tak1
Col2 mutants, we analyzed the expression of known
regulators of joint and cartilage development and quantified the
proliferation and apoptosis of mesenchymal cells within the
presumptive joint regions. In situ hybridization for specific
regulators of joint development, Wnt9a, Erg, andGdf5 (Fig.6A, A1
through A12) were performed on E14.5 sections. Wnt9a,a
molecule with antichondrogenic activity, is normally enriched in
the most medial layers of the interzone, as well as mesenchymal
populations surrounding the joint space (Fig. 6A, A1 and A7).
However, Tak1
Prx and Tak1
Col2 mutant embryos displayed only
weakWnt9aexpressioninsurroundingmesenchymaltissuesand
a complete loss of expression within the joint forming region
(Fig. 6A, A2 and A8). Gdf5 and Erg, molecules with chondrogenic
activities, are normally highly expressed in multiple layers of the
interzone, the articular cartilage, and within distinct wedges at
the sites of cavitation (Fig. 6A, A3, A5, A9, and A11). Interestingly,
Tak1
Prx and Tak1
Col2 mutants displayed dramatically reduced
Gdf5 expression throughout the presumptive interzone, whereas
Tak1
Col2 embryos maintained some expression in the surround-
ing mesenchyme (Fig. 6A, A4 and A10). On the other hand, Erg
expression was maintained at lower levels within cells of both
the presumptive interzone and surrounding mesenchyme
(Fig. 6A, A5, A6, A11, and A12).
To determine the cellular effects caused by misexpression of
these joint regulators, we performed proliferation (BrdU) assays,
apoptosis (TUNEL) assays, and in situ hybridization or immuno-
histochemical studies for markers of chondrocyte differentiation
on joint sections from Tak1
Prx mice. Our data demonstrate
that loss of Tak1 in the developing joint results in reduced
proliferation of the mesenchyme and chondrocytes within the
presumptive joint region (Fig. 6B, B1 and B2), but no significant
difference was observed for mesenchymal cell or chondrocyte
apoptosis (Fig. 6C). Owing to the aberrant chondrocyte-like cell
morphology found within the presumptive interzone of Tak1
Prx
mice, we assessed the expression of chondrocyte differentiation
markers on E14.5 joint sections. Immunohistochemistry for type
II collagen demonstrates a continuous expression profile of the
immature chondrocyte marker spanning the presumptive joint
region in Tak1
Prx mutants, whereas wild-type mice exhibit a
distinct break in type II collagen expression at the interface
of opposing cartilage elements (Fig. 6D, D3 and D4). In situ
hybridization analyses for aggrecan1 (Agc1), a marker of
maturing chondrocytes, revealed that the immature type II
collagen–expressing cells within the presumptive interzone
region of Tak1
Prx mutants do not express Agc1 (Fig. 6D, D5 and
D6). Both wild-type and Tak1
Prx mutants demonstrate that Agc1
expression is observed only in maturing chondrocytes adjacent
to the joint region at this stage. Finally, since we identified TAK1
as a regulator of BMP signaling in chondrocytes, and since the
BMP target gene noggin is important in joint development, we
performed in situ hybridization studies to determine the effect
that the absence of Tak1 has on noggin expression. Compared
with wild-type controls, Tak1
Prx mutant sections exhibit a
complete absence of noggin expression surrounding the
presumptive joint at E14.5 (Fig. 6D, D7 and D8). Therefore,
TAK1 represents an essential regulator of interzone formation
and/or maintenance, as well as, BMP signaling, during synovial
joint development.
Discussion
TAK1 regulates chondrocyte proliferation, maturation,
and apoptosis
In our model, cartilage removal of Tak1 (Tak1
Col2) resulted in
neonatal lethality, reduced chondrocyte proliferation, reduced
proliferating chondrocyte survival, and delayed chondrocyte
maturation within developing embryonic cartilages. It is of note
that a recent study by Shim and colleagues
(34) deleted Tak1 in
chondrocytes using a different Col2Cre transgenic line that
resulted in some similar cartilage phenotypes, except Shim and
colleagues
(34) observed these defects in only postnatal mutant
mice. The general similarities between the two studies include
decreased chondrocyte proliferation, general skeletal delay,
alterations inBMPandMAPKsignaling, andelbowabnormalities.
Criticaldifferences betweenthetwomodelsinclude theabilityof
their Tak1
Col2 mutants to survive postnatally for 2 to 3 weeks,
whereas our Tak1
Col2 mutants die prior to birth, and the timing
for the onset of cartilage phenotypes.
(34) Compared with the
previous study, it is likely that our mice exhibited an earlier
deletion of the Tak1 floxed alleles owing to the use of a different
Col2Cre transgenic mouse
(36,47) and therefore produced a more
profound and slightly different embryonic cartilage pheno-
type.
(34) Interestingly, our Tak1
Col2 mutants displayed a dramatic
phenotype during early stages of chondrocyte maturation
(E14.5) that appeared to diminish progressively at later stages of
development (E18.5). This is highlighted by the dramatic
decrease in chondrocyte proliferation ( 40%) that was later
restored to near-wild-type levels even in the presence of
continued TAK1 expression. Tak1
Col2 mutants also demonstrated
1792 Journal of Bone and Mineral Research GUNNELL ET AL.an increase in immature chondrocyte apoptosis that was not
evident in maturing chondrocytes. The combination of a
transient reduction in chondrocyte proliferation and increased
proliferating chondrocyte cell death may serve as an explanation
for the apparent temporary delay in chondrocyte maturation.
Although Tak1
Col2 mutants maintain identifiable cartilage
phenotypes until death at P0, it is difficult to ascertain whether
the in vivo chondrocyte maturation phenotype is progressive or
simply a reflection of the early proliferative and apoptotic
defects. Our in vitro studies examining the effects of loss or
inhibition of TAK1 on chondrocyte maturation suggest that the
delay in chondrocyte maturation is progressive and cannot be
accounted for solely by decreased proliferation and increased
proliferating chondrocyte apoptosis. In these experiments, cell
proliferation is reduced dramatically by days 3 to 4 in culture
owing to contact inhibition, and yet the progressive delay in
Fig. 6. TAK1regulatesproperinterzoneformation/maintenanceduringjointdevelopment.InsituhybridizationforWnt9a,Gdf5,andErginthedeveloping
humeroradial joint of E14.5 Tak1
Col2 (A1–A6) and Tak1
Prx (A7–A12) embryos. BrdU IHC of humeroradial joint of E14.5 Tak1
Prx embryos (B1) and
quantification from three sections each of wild-type and Tak1
Prx embryos (B2). (C) Representative TUNEL staining of humeroradial joint in E14.5 Tak1
Prx
embryos. (D) E14.5 humeroradial joint of Tak1
Prx embryos demonstrating H&E (D1, D2), Col2 IHC (D3, D4), Agc1 in situ hybridization (D5, D6), and noggin in
situ hybridization (D7, D8).
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observed in cultures well beyond this time point. Cell viability
was maintained throughout the culture period and thus cannot
account for the dramatically reduced levels of AP staining during
the 8-day differentiation period. Collectively, these data argue
that TAK1 continuously regulates the various stages of
chondrocyte proliferation, maturation, and apoptosis.
In addition to deletion of Tak1 in chondrocytes using the
Col2a1Cre transgenic mouse, we further investigated the effects
of TAK1’s regulation of embryonic chondrocyte maturation via
deletion of Tak1 in the developing limb mesenchyme using the
Prx1Cre transgenic mouse. Our additional analyses of Tak1
Prx
mutants revealed that these embryos recapitulated the Tak1
Col2
mutant limb cartilage phenotypes, although several additional
defects were observed, including a thinner perichondrium, a
disorganized and shortened columnar zone of chondrocytes, a
persistent reduction in chondrocyte proliferation, and an
expanded hypertrophic domain resulting from the delayed
progression in chondrocyte terminal maturation. Since the
Prx1Cre transgene targets both the chondrocytes and the
surrounding perichondrium, itis likelythat the additional defects
observed in the growth plates of Tak1
Prx embryos are due to
deletion of Tak1 within perichondrial cells and an imbalance in
signaling between these populations of cells. Several studies
have reported the importance of the perichondrium in
promoting organization of the columnar zone and regulating
chondrocyte proliferation and the progression to terminal
maturation. In fact, ex vivo organ culture experiments in both
chick and mouse have demonstrated that local removal or
experimental thinning of the perichondrium adjacent to the
prehypertrophic/hypertrophic domains leads to an expansion of
the hypertrophic region caused by a delay in the completion of
terminal hypertrophic differentiation.
(48,49) Additionally, genetic
removal of several signaling pathway components, including
Ihh/Pthrp,
(50–52) Wnt/b-catenin,
(39,53,54) and BMP/Smads
(15–20)
demonstrates that disruption in normal signaling events
between the perichondrium and chondrocytes often results in
delayed onset of chondrocyte hypertrophy and progression of
terminal maturation, as well as disorganization of growth plate
chondrocytes. Thus TAK1 appears to be required for normal
growth plate organization and terminal chondrocyte maturation
via maintenance of normal perichondrial development. The
exact function of TAK1 in the perichondrium during osteoblast
maturation is of great interest to our group and will be described
elsewhere.
TAK1 is required for MAPK and Smad 1/5/8 signaling
during cartilage development
In addition to the role for TAK1 in activating MKK3/6 and the
subsequent downstream MAPK signaling pathway component
p38, recent studies have found that TAK1 is capable of
interacting with all R-Smads (Smads 2/3 and Smads 1/5/8).
(55)
Both BMP and TGF-b pathways also can promote the activation
of TAK1 via noncanonical TGF-b/BMP signaling mechanisms.
(21)
What remains unclear is whether the noncanonical activation of
TAK1 works independently of, is required for, or signals in
opposition to the TGF-b/BMP canonical signaling pathways. If
TAK1 functions in a manner independent of TGF-b/BMP
canonical signaling during cartilage development, one would
expect that the growth plate phenotypes of our Tak1
Col2 and
Tak1
Prx mutants likely would resemble only those phenotypes
generated by inhibition of the MAPK signaling pathway.
Alternatively, if TAK1 is required for or signals in opposition to
canonical TGF-b/BMP signaling, we would have expected to
observe growth plate phenotypes resembling either TGF-b/BMP
loss- or gain-of-function mouse models, respectively. Interest-
ingly, we observed primarily growth plate phenotypes that
were consistent with disruptions in the BMP signaling pathways
during endochondral bone development. Comparison of Tak1
mutant growth plate phenotypes with those found in
Col2Cre;Bmpr1a
f/f;Bmpr1b
þ/  and Col2Cre;Smad1
f/f;Smad5
f/f
embryos reveals striking similarities, including the delayed
onset of chondrocyte hypertrophy, decreased proliferation, the
rarely observed increase in proliferating chondrocyte apoptosis,
disorganizationofcolumnarzonechondrocytes,andthedelayed
progression of terminal maturation
(16,17,20) (Fig. 7A). While
Col2Cre;Smad1
f/f;Smad5
f/f mutant phenotypes appear to be
significantly more severe than our Tak1 mutant mice, we reason
that these discrepancies are likely due to only a partial loss Smad
1/5/8 phosphorylation in Tak1
Col2 and Tak1
Prx mutants. It is also
of note that Col2Cre;Smad1
f/f;Smad5
f/f mutants show significant
decreases in the expression of MAPK components TAK1 and
MKK3, leading to the possibility that disruption of canonical BMP
signaling also disrupts noncanonical signaling.
(20) Many of the
Tak1 mutant phenotypes are recapitulated in these BMP
pathway mutants, although not all the skeletal phenotypes
are consistent. For example, the axial skeletal phenotypes,
including fusion of cervical vertebrae in Tak1
Col2 mutants and
loss of sternal midline fusion in Tak1
Prx mutants, strongly
resemble the phenotypes of mice deleted for Tgfbr2 using the
Col2Cre and Prx1Cre transgenes, respectively.
(12,13) Additional
roles for TAK1 in mediating TGF-b signals also may occur during
postnatal development, although we were unable to determine
whether this is the case becauseour mutants donot survive after
birth. Studies analyzing Col2Cre;Tgfbr2
f/f and Smad3
 /  mice
suggest that TGF-b plays a more prominent role in postnatal
growth and maintenance of cartilage.
(12,56) Finally, Tak1
Col2 and
Tak1
Prx mutants displayed variable MAPK loss-of-function
phenotypes similar to the dn-p38 and ATF2
 /  mice, although
most Tak1 mutant phenotypes were more pervasive and severe,
likely owing to the fact that TAK1 is upstream of both these
MAPK targets. Therefore, it seems plausible that TAK1 is an
important component in the functional crosstalk among the
MAPK, BMP, and TGF-b pathways in both temporal and tissue-
specific contexts during skeletal development.
Our signaling studies, as well as those performed by Shim and
colleagues,
(34) provided further support for the importance of
TAK1 in mediating BMP activation of Smad 1/5/8 and p38 via
noncanonical signaling mechanisms. While the suppression of
Smad 1/5/8 activation is incomplete on TAK1 inhibition, the
significant decrease in activity suggests that TAK1 is at least one
of the critical components by which BMP signals activate R-
Smads. Interestingly, p38 activation is completely absent in both
normal and BMP-induced chondrocytes following TAK1 inhibi-
tion, indicating the importance of TAK1 during normal MAPK
1794 Journal of Bone and Mineral Research GUNNELL ET AL.signaling and noncanonical BMP signaling (summarized in
Fig.7B).Theseverelyimpairedchondrocytematurationobserved
in TAK1 mutant cultures supports a role for TAK1 in the
promotion of chondrocyte hypertrophy, which is in line with the
function of BMP signaling on chondrocyte maturation and not
that of the suppressive function for TGF-b. Additionally, TAK1
mutant chondrocytes were unable to respond to BMP-induced
maturation (Fig. 3D, E), but the ability of TGF-b to inhibit
chondrocyte maturation was well preserved (Fig. 3D). These data
suggestthatTAK1mutantchondrocytesarelesssensitivetoBMP
signaling and therefore are impaired in their ability to undergo
chondrocytematuration.Interestingly,studiesincardiomyocytes
also have demonstrated the requirement for TAK1 in mediating
BMP-induced differentiation.
(57) Furthermore, our in vivo data
indicate that fewer columnar and hypertrophic chondrocytes
displayed significant levels of phosphorylated Smad 1/5/8
proteins in the nuclei of Tak1
Col2 and Tak1
Prx mutants. It is
therefore intriguing to speculate that reduced BMP/Smad
signaling in the cartilage of Tak1 mutant mice accounts for
the decreased chondrocyte proliferation, increased proliferating
chondrocyte apoptosis, and delayed onset of maturation.
TAK1 regulates interzone and joint development
Defects in joint formation observed in Tak1
Col2 and Tak1
Prx
embryos provide direct evidence for the importance of TAK1
signaling during the process of joint formation. While several
signalingmoleculeshavebeenimplicatedininterzoneformation
and synovial joint development, the molecular mechanisms
underlying these processes remain not well understood. Cells at
the site of prospective joints form the mesenchymal interzone.
Interzone cells and the surrounding mesenchymal tissues act as
signaling centers expressing both antichondrogenic molecules
(Wnt9a and noggin) that aid in maintaining the interzone and
chondrogenic factors (Gdf5, Erg, and various members of the
BMP family) that promote chondrocyte differentiation of the
adjacent cartilage. What is clear is that an appropriate balance of
these factors must be maintained in order for synovial joints to
initiate and develop properly. Molecular analyses of both
the Tak1
Col2 and Tak1
Prx mutant joints revealed a loss of the
antichondrogenic gene Wnt9a and Noggin specifically within
the developing interzone. Additionally, these mutants lacked
significant expression of Gdf5, although chondrogenic factors
such as Erg, which is known to promote and maintain an early
chondrogenic phenotype, were maintained at low levels in the
surrounding joint tissue but also within the presumptive
interzone. Therefore, loss of Tak1 may lead to an imbalance of
antichondrogenic and chondrogenic factors that favors chon-
drogenesis, the maintenance of an early chondrogenic pheno-
type, and the subsequent loss of interzone cells.
Analyses of the Tak1
Col2 mutant mice revealed fusions and
malformations only at the humeroradial joints, whereas Tak1
Prx
mutantsexhibitedjointfusionsatnearlyallsynovialjointsexcept
thoseofthedigits.Webelievethattheelbowjointisfusedwithin
Tak1
Col2 mutant mice owing to the promiscuity of the Col2Cre
transgene in early mesenchymal cells of that particular joint
region, as demonstrated previously using a Col2Cre;R26R
reporter mouse.
(40) Tak1
Prx mutant mice have more widespread
defects in synovial joints because the Prx1Cre transgene targets
nearly all mesenchymal progenitors prior to joint site determina-
tion (Supplemental Fig. 1C). These Tak1
Prx mutants strongly
resemble the joint phenotypes derived from Prx1Cre;Bmp2
f/
f;Bmp4
f/f and Gdf5
 /  mutant mice, displaying joint fusions and
impaired interzone formation/maintenance at nearly all synovial
joints.
(14) In addition, our analyses demonstrate a severe
reduction in the expression of the BMP target gene noggin in
the developing joint region; therefore, it is likely that TAK1
regulates BMP signaling not only in the growth plate but also at
sites of joint formation. It is unlikely that the joint defects
observed in these Tak1 mutants are due to defective TGF-b or
MAPK signaling because mutations in these signaling circuits
either do not produce joint fusion abnormalities
(33) or the
malformations are restricted primarily to joints of the digits,
(12)
which are not affected in Tak1 mutants.
In this study and through the work of Shim and colleagues,
(34)
we have provided the first in vivo genetic evidence that TAK1
is a critical component of both the MAPK and BMP signaling
Fig. 7. Summary of TAK1 signaling and regulation of cartilage develop-
ment.(A) Cells are color coded as follows: Round blue cells are immature/
slowly proliferating chondocytes; flat blue cells are columnar, highly
proliferative chondrocytes; purple cells are prehypertrophic chondro-
cytes; green cells are hypertrophic chondrocytes; orange cells indicate
terminally hypertrophic chondrocytes; black cells indicate trabecular
osteoblasts;redcellsindicatebonemarrow;andtheyellowareaindicates
maturing bone collar. Numbers in light blue circles indicate chondrocyte-
specific effects of TAK1, and numbers in white circles are perichondrial
effects of TAK1. (B) TAK1 signaling via the MAPK and BMP pathways. Red
arrows indicate canonical and noncanonical BMP signaling regulation;
black arrows indicate MAPK signaling via TAK1.
TAK1 REGULATES SKELETAL DEVELOPMENT Journal of Bone and Mineral Research 1795pathways during embryonic cartilage and joint development, as
well as during early postnatal cartilage regulation.
(34) Further-
more, our model extends the developmental analysis via use of
the Tak1
Prx mouse model. These mice demonstrate that TAK1
signaling is not only critical for the development of nearly all
synovial joints but also required in the surrounding limb
mesenchyme to control several aspects of chondrocyte
proliferation and differentiation. Finally, since our unique
observations during skeletal development demonstrate clear
similarities to the phenotypes observed in several other models
of developmentinwhich BMPsignaling isdeficient, they confirm
aninvivophysiologicroleofTAK1inBMP/Smadsignalingduring
limb and joint development. Our continuing studies will aid in
elucidating the TAK1-mediated effects on perichondrial or
osteoblast maturation, axial skeletal development, and
joint formation and the potential role of TAK1 in cartilage
maintenance and disease.
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